Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12616604 | 0.82 | IMPDH2 (0.41) | IMPDH2ABL1KDRELANESMN1; SMN2 | |
| SCHEMBL29026945 | 0.81 | IMPDH2 (0.40) | IMPDH2ABL1KDRELANESMN1; SMN2 | |
| SCHEMBL21069209 | 0.80 | SMN1; SMN2 (0.35) | HSD17B10ABL1KDRCHEK1ELANE | |
| SCHEMBL29086594 | 0.78 | ELANE (0.59) | CHEK1ELANESMN1; SMN2GAA | |
| SCHEMBL29890000 | 0.78 | ELANE (0.59) | CHEK1ELANESMN1; SMN2GAA | |
| SCHEMBL14884084 | 0.76 | HSD17B10 (0.43) | GSK3BHSD17B10ABL1KDRCHEK1 | |
| SCHEMBL15257723 | 0.75 | LRRK2 (0.48) | — | |
| SCHEMBL29026900 | 0.75 | GAA (0.43) | IMPDH2EGFRERBB2GAA | |
| SCHEMBL8511931 | 0.75 | CHEK1 (0.33) | HSD17B10ABL1KDRCHEK1 | |
| SCHEMBL20610577 | 0.75 | HSD17B10 (0.42) | GSK3BHSD17B10ABL1KDRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | GSK3B 227/4885IMPDH2 4142/4885HSD17B10 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.